In a multicenter study of nearly 25,000 diabetic patients with brain aneurysms, GLP-1 receptor agonist use was associated with a 38% lower risk of aneurysm rupture at 3 years and 35% lower at 5 years.
38% lower rupture risk at 3 yearsGLP-1 receptor agonist users had a 38% lower risk of subarachnoid hemorrhage from brain aneurysm rupture compared to matched non-users — a significant protective association in a large multicenter cohort.
What the researchers found
From 24,776 T2DM patients with unruptured intracranial aneurysms identified in the TriNetX Research Network, propensity score matching produced 2,651 patients in each group (GLP-1RA users vs. non-users).
GLP-1RA use was associated with significantly reduced risk of nontraumatic subarachnoid hemorrhage (SAH):
- 3-year follow-up: HR 0.62 (95% CI: 0.44–0.88) — 38% risk reduction
- 5-year follow-up: HR 0.65 (95% CI: 0.47–0.92) — 35% risk reduction
Follow-up laboratory values showed no significant differences between groups, suggesting the protective effect is not simply mediated by metabolic improvements.
Why it matters
Brain aneurysm rupture is one of the most feared neurological emergencies, with about 50% mortality. Currently, the only way to prevent rupture is surgical clipping or endovascular coiling — invasive procedures with their own risks. If GLP-1 drugs can stabilize aneurysms and reduce rupture risk through a simple medication, it could transform management for the millions of people living with unruptured brain aneurysms.
How the study worked
This multicenter retrospective cohort study used the TriNetX Research Network to identify adults with type 2 diabetes and unruptured intracranial aneurysms between 2008 and 2025. Patients were classified as GLP-1RA users or non-users. One-to-one propensity score matching balanced demographics, comorbidities, laboratory values, and medication use. The primary outcome was nontraumatic subarachnoid hemorrhage at 3 and 5 years.
What this study cannot tell us
This is a retrospective observational study that cannot prove causation. Despite propensity score matching, unmeasured confounders may exist. The study used administrative diagnosis codes for SAH, which may have coding inaccuracies. It cannot determine whether GLP-1 RAs prevent aneurysm formation, growth, or rupture specifically. Aneurysm size, location, and morphology were not controlled for. The study population was limited to T2DM patients, so results may not generalize to non-diabetic individuals.
How to read the evidence
This is a large multicenter retrospective cohort study with propensity score matching, providing moderate-strength observational evidence. The large sample size and consistent effect across time points strengthen the findings, but prospective and imaging-based studies are needed to confirm the association.
When this study was published
Published in 2026 using data through 2025, this is very recent research at the forefront of GLP-1 RA vascular biology, addressing a question that has not been studied in large human cohorts before.
The bigger picture
This study adds vascular wall stabilization to the growing list of GLP-1 RA benefits beyond metabolic control. The finding aligns with preclinical evidence of GLP-1's anti-inflammatory and vascular protective effects, and suggests these drugs may influence blood vessel remodeling. If confirmed, it could establish a new pharmacological approach to aneurysm management — a field that currently relies almost entirely on surgical intervention and watchful waiting.
Questions still open
- Do GLP-1 receptor agonists stabilize aneurysm walls through anti-inflammatory mechanisms, or do they prevent growth and rupture through other pathways?
- Would GLP-1 drugs reduce aneurysm rupture risk in non-diabetic patients with brain aneurysms?
- Could GLP-1 RAs become part of the management strategy for patients with incidentally discovered unruptured aneurysms who are being observed?
Common questions
Can GLP-1 drugs like semaglutide prevent brain aneurysm rupture?
How might GLP-1 drugs protect against brain aneurysm rupture?
Read the original research
GLP-1 receptor agonists and aneurysm rupture risk in type 2 diabetes: a multicenter retrospective study.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 147, 111905
Citation
Li, Sean Y; Sonti, Anisha; Kaelber, David C; Ben-Israel, David; Bowles, Alfred; Reddy, Deven; Kelly, Michael L. (2026). GLP-1 receptor agonists and aneurysm rupture risk in type 2 diabetes: a multicenter retrospective study.. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 147, 111905. https://doi.org/10.1016/j.jocn.2026.111905